Dynamic Prediction Model
2
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Systemic Chemotherapy Combined With Immunotherapy
Research Leaders
10 sponsors active, led by Zhejiang Cancer Hospital
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 2 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal Surgery Using Longitudinal Indices of Routine Blood Tests: A Single-Center Retrospective Cohort Study
Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study
Research Network
Common Treatments
- Systemic Chemotherapy Combined With Immunotherapy1
Active Sponsors
- Zhejiang Cancer Hospital1
- Zhongda Hospital1
- The First Affiliated Hospital, University of Science and Technology of China1
- Jiangsu Cancer Institute & Hospital1
- The Third Affiliated Hospital of Soochow University1
Top Investigators
Zhongda hospital, Southeast university, Nanjing, China
Related Conditions
- Immunotherapy1
- Unresectable Biliary Tract Cancer1
- Crohn Disease Cd1